New vaccine aims to shield stem cell patients from dangerous virus
NCT ID NCT07020533
First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 8 times
Summary
This early-phase trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV) and prevent active infection after a half-matched stem cell transplant. About 46 people with various blood cancers will take part. The goal is to see if the vaccine is safe and helps reduce CMV-related complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACCELERATED PHASE CHRONIC MYELOID LEUKEMIA, BCR-ABL1 POSITIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02215, United States
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
-
Northside Hospital
RECRUITINGAtlanta, Georgia, 30342, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can trained immune cells stop blood cancer relapse?
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Could muscle loss predict blood cancer outcomes?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a modified enzyme starve Hard-to-Treat blood cancers?